November 2018 Vol 9, NO 11
A navigator’s interventions with a patient throughout treatment include disease-specific education packet, referrals to specialists, resources and supportive care team members, providing timely appointments, presentation at Breast Tumor Board, chemotherapy education, and performing a treatment summary.
Jillian Kenney-Lueptow, BSN, RN, OCN, Jason Kulangara, MBA, MSN, RN, Laura Alfonso, RN, MSN, OCN, Samantha Thomas, RN, BSN, OCN, Rebecca Hoh, RN, BSN, OCN, Franz Cordero, RN, BSN, OCN, Patricia Jakel, RN, MSN, AOCN
An inpatient oncology unit had consistently low patient satisfaction ratings regarding patient education.
Kenyatta National Hospital (KNH) is the only public hospital in Kenya delivering comprehensive cancer care and receives patients from throughout the country.
Genetic testing has become an important component to determining treatment options.
Early recognition of malnutrition and preoperative nutritional status is paramount in improving surgical outcomes.
Kristi C. Garrison, MS, CHES, CHW, OPN-CG, Stacey L. Webb, MPA-HCA, BSN, RN, ONN-CG, Nora J. Barrett, BSN, RN, OCN, ONN-CG, Kristi M. Griffith, MSN, RN, CHPN, OON-CG
The specialized field of patient navigation (PN) is evolving into an essential role in the oncology patient care continuum.
According to the American Cancer Society Facts & Figures 2018, lung cancer is the leading cause of death in men and women in the United States.
Oncology navigation is a patient-focused, time-intensive process.
Debbie Jacobson, OPN-CG, Katy Engelby, BA, Katie Schoeppner, MSW, LICSW, Ellen Denzen, MS, Elizabeth Murphy, EdD, RN
Blood and marrow transplant (BMT) patients encounter many barriers while accessing curative treatment.
Patient acuity tools have been used to classify patients according to care needs to serve a variety of purposes.
Susan G. Häag, PhD, MS, Tricia Strusowski, RN, MS, Alyssia Crews, MBA, Beth High, MSN, RN, OCN, CBCN, CN-BN
Patient navigation has been shown to improve patient engagement and enrollment in clinical trials and increase supportive cancer care.
Employee engagement is a key element of success among businesses and organizations.
Offering patients access to oncology navigation is not only recommended, it is also a requirement for certification of oncology programs endorsed by 2 national organizations.
The orientation/onboarding process is neither standardized nor well understood across the oncology navigation industry.
There is extensive literature in change and transition management in leadership but limited literature from a non-managerial or navigator’s point of view.
Benefits of a Multidisciplinary Survivor Clinic in Addressing Quality of Life After Cancer Treatment
Laura Beaupre, RN, BSN, OCN, CN-BN, Jane Zubia, RN, OCN, CN-BN, Kathleen Sevedge, RN, MA, AOCN, Eileen Steirer, Alyssa Pauls, RN, BSN, OCN, Cynthia Smith, RN, BSN, OCN, MA, Maritza Chicas, RN, BSN, OCN, Jeanne Kenna, RN, OCN, CRNI, Angela Miller, RN, BSN, OCN, MEd, Raizalie Roman, RN, BSN, OCN
“Care of the cancer survivor should include prevention, surveillance, assessment of late effects and intervention for consequences of cancer and treatment.”
Kay Hankins, RN, Jolene Hetsler, RN, ONS, Cynthia Kuhn, RN, CBCN, MaryAnn Pedersen, RN, Beth Matthews, MSN, RN, OCN
Advance care planning (ACP) is central to patient-centered care and improves alignment between patient preferences and care received at end-of-life.
A recent needs assessment for Camden County, NJ, shows that residents’ compliance with cancer screening recommendations for colon (65%), breast (73%), and cervical (74%) cancers does not meet Healthy People 2020 guidelines.
Palliative care is a collaborative approach that improves quality of life for patients and families but is often provided too late.
Carol Del Campo, RN, BSN, OCN, Kevin Schreffler, MSN, RN, OCN, Dawn Hayes, PT, PhD, GCS, Donna Meyer, BSN, MS, Bryan Miller, MSW, LCSW, OSW-C, Amy Sickles, PA-C, Mildred Nunez Jones, BA, CTR, Hiba Tamim, MD
The Academy of Oncology Nurse & Patient Navigators (AONN+) promotes the goal to share best practices for survivorship and to address the question “Does the Survivorship Care Plan (SCP) meet patient goals?” (Staci Oertle, RN, MSN, APN, AOCNP, AONN+ Survivorship Committee).
With the increasing cancer survivor population comes the need to develop recommendations about how to optimally care for these survivors.
Caitlin Mason, PhD, Jennifer Haase Morris, MBA, Marlee Fisher, MPH, Patti Migliore Santiago, MAOM, Peggy Hannon, PhD, MPH
Survivorship care recommendations exist to support a large and growing population of cancer survivors, yet little is known about survivors’ ongoing unmet needs.
Katie Narvarte, LMSW, OSW-C, OPN-CG, Emily Gentry, BSN, RN, HON-ONN-CG, OCN, Jordan Henderson, BSN, RN, OCN, ONN-CG, Cristina Laviada, RN, BSN, Mike Ashworth, PhD
In 2005, the Institute of Medicine published “From Cancer Patient to Cancer Survivor: Lost in Transition.” The report highlights the long-term medical and psychosocial consequences of cancer treatment and provides a foundation for survivorship programs today.
Thoracic surgeons remain involved with the long-term care of their cancer patients, usually in surveilling for recurrence. However, with an increasing survivor population, little is known on their other supportive needs.
Arin Ahlum Hanson, MPH, Lori Ranallo, RN, MSN, APRN-BC, CBCN, Karen Werner Carera, PhD, Betsy Smither, MPH, CHES, Jennifer Reynolds, MPH, CHES, Ingrid Mapanao
Women diagnosed with breast cancer before age 45 face unique survivorship challenges, including early menopause, late effects of treatment, psychosocial distress, and sex and intimacy changes.
The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway is frequently activated in breast cancer and can promote tumor growth, progression, and resistance to anticancer therapies such as endocrine therapy (ET).
David E. Gerber, MD, Martin Reck, Matthew D. Hellmann, Luis Paz-Ares, Hossein Borghaei, Julie Brahmer, Kenneth J. O'Byrne, Prabhu Bhagavatheeswaran, Faith Nathan, Suresh S. Ramalingam
CheckMate 227 (NCT02477826) is a large phase 3 study of first-line nivolumab or nivolumab-based regimens vs chemotherapy in advanced NSCLC.
Multiple tyrosine kinase inhibitors (TKIs) that target the BCR-ABL1 ATP-binding site are available for treating chronic myeloid leukemia (CML).
The COMBI-AD trial demonstrated that adjuvant treatment with dabrafenib + trametinib (D+T) in patients (pts) with resected stage III BRAF-mutant melanoma significantly reduced the risk of melanoma recurrence vs placebo (PBO).
Dirk Schadendorf, MD, Axel Hauschild, MD, Mario Santinami, MD, Victoria Atkinson, MD, Mario Mandalà, MD, Vanna Chiarion Sileni, MD, James Larkin, MD, PhD, Marta Nyakas, MD, Caroline Dutriaux, MD, Andrew Haydon, MD, PhD, Laurent Mortier, MD, Caroline Robert, MD, PhD, Jacob Schachter, MD, Ran Ji, Paola Aimone, Stephanie Manson, Richard Kefford, MD, PhD, Reinhard Dummer, MD, John M. Kirkwood, MD, Georgina V. Long, MD, PhD
Adjuvant treatment (tx) of resected stage III BRAF-mutant melanoma with dabrafenib + trametinib (D+T) significantly reduced the risk of recurrence vs placebo (PBO).
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512